Literature DB >> 9406323

How a general population perceives its sleep and how this relates to the complaint of insomnia.

M M Ohayon1, M Caulet, C Guilleminault.   

Abstract

The traditional indicators of insomnia (i.e. difficulty initiating sleep, difficulty maintaining sleep, nonrestorative sleep, early morning awakening) were assessed in a representative sample of 1,722 French-speaking Montrealers (Canada) aged 15 to 100 years. These subjects were interviewed over the telephone (81.3% of contacted sample) by means of the Sleep-Eval software. Subjects were classified as either satisfied or dissatisfied with quality of sleep (SQS or DQS), with or without insomnia indicators (+I or -I). Sociodemographics, sleep-wake schedules, evening activities, medication intake, recent medical consultations, and social life were also investigated. DQS subjects composed 17.8% of the population (DQS + I: 11.2%; DQS - I: 6.5%), and 21.7% of subjects were classified as either DQS + I or SQS + I. Overall, 3.8% of subjects reported using a sleep-enhancing medication. Nonrestorative sleep did not significantly distinguish SQS and DQS subjects. The complaint of nonrestorative sleep is not a useful indicator of insomnia, despite its inclusion in all medical classifications. DQS - I and SQS + I subjects defy traditional classifications. A better understanding of sleep complaints and more accurate classifications will help physicians identify patients with insomnia and meet their needs more appropriately.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406323     DOI: 10.1093/sleep/20.9.715

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  25 in total

1.  Ramelteon: a novel hypnotic indicated for the treatment of insomnia.

Authors:  Gary K Zammit
Journal:  Psychiatry (Edgmont)       Date:  2007-09

2.  Racial/Ethnic Differences in Sleep Disorders and Reporting of Trouble Sleeping Among Women of Childbearing Age in the United States.

Authors:  Melissa Amyx; Xu Xiong; Yiqiong Xie; Pierre Buekens
Journal:  Matern Child Health J       Date:  2017-02

3.  Efficacy and tolerability of indiplon in transient insomnia.

Authors:  Russell Rosenberg; Thomas Roth; Martin B Scharf; D Alan Lankford; Robert Farber
Journal:  J Clin Sleep Med       Date:  2007-06-15       Impact factor: 4.062

4.  Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD).

Authors:  Maurice M Ohayon; Charles F Reynolds
Journal:  Sleep Med       Date:  2009-10       Impact factor: 3.492

5.  Insomnia and the performance of US workers: results from the America insomnia survey.

Authors:  Ronald C Kessler; Patricia A Berglund; Catherine Coulouvrat; Goeran Hajak; Thomas Roth; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh
Journal:  Sleep       Date:  2011-09-01       Impact factor: 5.849

6.  The effects of physical activity on sleep: a meta-analytic review.

Authors:  M Alexandra Kredlow; Michelle C Capozzoli; Bridget A Hearon; Amanda W Calkins; Michael W Otto
Journal:  J Behav Med       Date:  2015-01-18

Review 7.  Residual effects of hypnotics: epidemiology and clinical implications.

Authors:  Annemiek Vermeeren
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Prevalence, course, and comorbidity of insomnia and depression in young adults.

Authors:  Daniel J Buysse; Jules Angst; Alex Gamma; Vladeta Ajdacic; Dominique Eich; Wulf Rössler
Journal:  Sleep       Date:  2008-04       Impact factor: 5.849

9.  A community-based cross-sectional study of sleep quality in middle-aged and older adults.

Authors:  Hui-Shan Zhang; Yuan Li; Hai-Yun Mo; De-Xing Qiu; Jing Zhao; Jia-Li Luo; Wei-Quan Lin; Jia-Ji Wang; Pei-Xi Wang
Journal:  Qual Life Res       Date:  2016-09-12       Impact factor: 4.147

10.  Insomnia and role impairment in the community : results from the Nigerian survey of mental health and wellbeing.

Authors:  Oye Gureje; Victor A Makanjuola; Lola Kola
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2007-04-21       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.